Evaluation Pembrolizumab (Keytruda): CADTH Reimbursement Suggestion: Indicator: In combination with chemotherapy, for that remedy of Grownup patients with regionally recurrent unresectable or metastatic triple-negative breast most cancers that have not gained prior chemotherapy for metastatic illness and whose tumours Categorical programmed mobile death-ligand 1 (mixed beneficial rati... https://thomasy356ool6.wikissl.com/user